Profile
Marina Udier currently works at Nouscom AG, as Chief Executive Officer & Director from 2020, Nouscom Srl, as Chief Executive Officer & Director, and Celyad Oncology SA, as Independent Director from 2011.
Dr. Udier also formerly worked at Novartis AG, as Head-Global Commercial and Versant Venture Management LLC, as Chief Operating Officer.
Dr. Udier received her doctorate degree from Yale University.
Marina Udier active positions
| Companies | Position | Start |
|---|---|---|
| CELYAD ONCOLOGY SA | Director/Board Member | 11/01/2011 |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Operates as an oncology company that develops immunotherapies | Chief Executive Officer | 01/05/2019 |
Nouscom Srl
Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer | Chief Executive Officer | - |
Former positions of Marina Udier
| Companies | Position | End |
|---|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Chief Operating Officer | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Training of Marina Udier
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Novartis AG
Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Finance |
Celyad Oncology SA
Celyad Oncology SA BiotechnologyHealth Technology Develops immuno-oncology and cardiology products | Health Technology |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Operates as an oncology company that develops immunotherapies | Health Technology |
Nouscom Srl
Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer | Commercial Services |
- Stock Market
- Insiders
- Marina Udier
















